biotech

AstraZeneca has invested $2bn in US biotech firm Summit Therapeutics as part of a major cancer research collaboration. The FTSE 100 drugmaker agreed to buy 109,000 shares in the Nasdaq-listed company at $18.36 per share, funding a tie-up aimed at developing new cancer treatments.

Beam Therapeutics says a scientist took trade secrets and used them to help launch a rival startup in China. The allegation, reported by Bloomberg Law, adds to ongoing tensions between US biotech firms and China over intellectual property. Details of the accused scientist's identity and the specific secrets involved were not disclosed in the available reporting.

OpenAI has led a $150 million funding round for Biossil, a startup working on reviving discontinued drugs. The deal marks a further push by OpenAI into applying its technology beyond core AI products, with biotech being a notable target area.

A report examines how China has rapidly become a leading force in health technology, spanning AI healthcare applications, biotech, and drug development. The piece argues that China's growing dominance in medical innovation carries major implications for global healthcare, competition, and the future of drug discovery, a point resonating with technology readers discussing the story online.

Immunology startup ai3Bio is drawing attention with its stated goal of redefining what it means to reset the immune system. The company is positioning itself in the emerging field of immune-reset therapies, an area of growing interest for treating autoimmune and inflammatory diseases. Details about funding, clinical programs and the science behind its approach have not yet been widely reported, so observers are watching for more information.

Japanese pharmaceutical company Shionogi has agreed to pay $2 billion to acquire a rare disease startup. The deal signals Shionogi's push to expand its pipeline beyond its core infectious disease focus into specialty and rare disease treatments. The acquisition adds to a broader wave of large pharma buyouts of biotech firms developing therapies for small patient populations with high unmet needs.

China's growing biotechnology companies are presenting themselves to international investors and partners from Shanghai's Zhangjiang district, known as the city's 'Science City.' Reports from STAT and The Boston Globe highlight how these ascendant firms are showcasing drug development capabilities and seeking global recognition as China's life sciences sector expands its international ambitions.

Spyre Therapeutics, Inc. (SYRE) is drawing attention from investors tracking its stock price, news, quotes and trading history. The clinical-stage biotech, which develops treatments for inflammatory bowel disease, is being closely watched as traders look up its latest market performance and company updates.

Barron's rounds up the stocks explaining today's market action, including Apple, Meta, Iovance, Carnival, Fair Isaac, Bloom Energy and SpaceX. The list spans big tech, biotech, travel and energy, pointing to a broad trading day driven by company-specific news across several sectors rather than a single dominant story.

Kodiak Sciences announced that its experimental eye drug performs on par with Regeneron's established treatment, according to a Benzinga report. The claim, if supported by trial data, would position the biotech as a credible challenger in the competitive market for retinal disease therapies, where Regeneron's medicine has long been a dominant option.

Japanese biotech startup Celaid Therapeutics has completed the second close of its Series B financing round, bringing in an additional $2.6 million. The company, which is developing regenerative medicine therapies, did not disclose the investors involved. The funding will support its push to advance its cell-based treatment pipeline, though specific allocation details were not announced.

Researchers have developed a deep learning tool that reads the regulatory code of leukemia cells to predict patient risk. By analyzing how genetic regulatory elements behave in cancer cells, the model aims to forecast how the disease will progress in individual patients. Such tools could help doctors tailor treatment intensity and identify high-risk cases earlier, though details on validation and clinical use remain limited.

Retail investors are speculating about small-cap biotech stocks Sellas Life Sciences (SLS) and ImmunityBio (IBRX) after Moderna (MRNA) was added to the Nasdaq-100 index. Some traders are betting one of the two could be next to earn a spot in the benchmark index, fueling buzz around the names on social trading platforms. Index inclusion typically drives demand from funds tracking the Nasdaq-100, which is why traders watch additions closely for potential stock moves.

BridgeBio is teaming up with Hip Hop Public Health and other partners to launch a new awareness campaign for ATTR-CM, a rare heart condition caused by amyloid buildup. The initiative will use music-based outreach to educate communities about the disease's symptoms and the importance of diagnosis, aiming to reach audiences often missed by traditional health messaging.

Swiss pharmaceutical giant Novartis has signed a deal worth $7.8 billion with a Chinese drug startup. The agreement, reported by Axios, underscores the growing role of Chinese biotech companies in global drug development and Novartis's strategy of licensing experimental medicines from abroad. Details about the specific drug and startup have not been confirmed in available reports.

Immunology startup TRex Bio has set the price range for its planned initial public offering, which would raise around $133 million. The debut will put the spotlight on investor appetite for biotech listings, with the company developing treatments based on immune-regulation science. Details on valuation and listing timing are expected as the offering books are built.

Microsoft has introduced Quine, an AI system aimed at biotech research and development, according to reports. The move is described as intensifying competition among major technology companies, including Google and other rivals, that are pushing AI tools into drug discovery and biological science. Analysts suggest the entry could accelerate a broader race to apply AI to pharmaceutical and biotech research.

South Korea's startup funding in the third quarter of 2026 showed a sharp sector shift, with robotics companies attracting a surge in investment while large-scale biohealth deals disappeared from the market. The report highlights how venture capital attention is moving away from biotech mega-rounds toward automation and robotics, a change that could reshape the country's startup funding landscape going forward.

Australian biotech giant CSL is reported to be weighing a deal worth up to $2.2 billion with a Swiss biotech start-up, according to the Australian Financial Review. The arrangement would centre on rights to a drug candidate, adding to CSL's pipeline as it looks for new growth areas beyond its established plasma-based therapies.

The FDA plans to highlight aging and longevity medicine in upcoming updates to the Federal Acquisition Regulation Supplement (FARS), according to a report by Genetic Engineering and Biotechnology News. The move signals growing regulatory attention to treatments targeting aging itself rather than individual age-related diseases, a field attracting increased investment and research interest.

Biogen Inc.'s stock price, quote and trading history are being widely tracked on financial platforms, with investors monitoring the biotech company's share movements and latest news. Traders typically follow the Cambridge, Massachusetts-based firm closely around earnings, drug development updates and regulatory decisions affecting its pipeline. No specific price move or corporate event is cited in the available reports.

Novavax shares are being tracked by investors on the Frankfurt exchange under ticker NVV1.F, where the biotech's price, quote and history are being monitored amid ongoing interest in the company's outlook. Novavax, known for its COVID-19 vaccine business, has faced volatile trading in recent years as it works to stabilise revenue, and market watchers are following its stock movements closely.